TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Trading Down 26.0 %

Shares of TCON stock opened at $0.03 on Monday. The firm has a market capitalization of $109,802.00, a PE ratio of 0.01 and a beta of 1.37. The firm has a fifty day simple moving average of $0.04 and a two-hundred day simple moving average of $0.33. TRACON Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $14.75.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.